For IF: Use at a concentration of 1.5 - 2.5 μg/ml. For IHC-P: Use at a concentration of 4 - 6μg/ml. For IHC-Fr: Use at a concentration of 4 - 6μg/ml. For IP: Use at a concentration of 3 - 5μg/ml. Not suitable for use in Western Blot. Optimal dilutions/concentrations should be determined by the researcher.
Sw480 or Y1 cells or normal skin tissue.
Reactive with the p21 translational products of the H-, K- and N-ras human, as well as mouse and rat c- and v-ras oncogenes.
0.05 M sodium phosphate buffer, 0.2% gelatin with =0.1% sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
0.1 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant full length protein (Human).
Protein A purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
K-RAS Antibody , RASH1 Antibody , HAMSV Antibody , HRAS Antibody , C-HA-RAS1 Antibody , C-BAS/HAS Antibody , N-RAS Antibody , CTLO Antibody , C-H-RAS Antibody , H-RASIDX Antibody , HRAS1 Antibody , C-K-RAS Antibody , NS Antibody , KRAS1 Antibody , K-RAS4A Antibody , KRAS Antibody , KI-RAS Antibody , KRAS2 Antibody , K-RAS2B Antibody , NS3 Antibody , K-RAS2A Antibody , K-RAS4B Antibody , RASK2 Antibody , NRAS Antibody , NRAS1 Antibody , N-RAS Antibody , ALPS4 Antibody , NS6 Antibody
This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for